These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9433385)

  • 1. Comparative regulation of drug and aircraft development: lessons for regulatory reform?
    Urquhart J
    Clin Pharmacol Ther; 1997 Dec; 62(6):583-6. PubMed ID: 9433385
    [No Abstract]   [Full Text] [Related]  

  • 2. Prepare for the long haul of drug monitoring.
    Gliklich R
    Nat Med; 2010 Aug; 16(8):848. PubMed ID: 20689542
    [No Abstract]   [Full Text] [Related]  

  • 3. The Food and Drug Administration's use of postmarketing (Phase IV) study requirements: exception to the rule?
    Steenburg C
    Food Drug Law J; 2006; 61(2):295-383. PubMed ID: 16903034
    [No Abstract]   [Full Text] [Related]  

  • 4. Reforms on drug safety.
    Nature; 2006 Sep; 443(7110):372. PubMed ID: 17006474
    [No Abstract]   [Full Text] [Related]  

  • 5. Roadmap for revitalization?
    Nat Biotechnol; 2007 Oct; 25(10):1061. PubMed ID: 17921973
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug approval system questioned in US and Canada.
    Eggertson L
    CMAJ; 2005 Feb; 172(3):317-8. PubMed ID: 15684107
    [No Abstract]   [Full Text] [Related]  

  • 7. US Senate passes FDA Revitalization Act.
    Guthrie P
    CMAJ; 2007 Jul; 177(1):23. PubMed ID: 17606930
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 9. StatBite. FDA-required postmarketing studies, 1992-2008.
    J Natl Cancer Inst; 2010 Sep; 102(17):1303. PubMed ID: 20739654
    [No Abstract]   [Full Text] [Related]  

  • 10. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA tightens its grip on drug regulation.
    Coombes R
    BMJ; 2007 Feb; 334(7588):290-1. PubMed ID: 17289729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense.
    Viscusi WK; Rowland SR; Dorfman HL; Walsh CJ
    Spec Law Dig Health Care Law; 1996 Mar; (205):9-52. PubMed ID: 10156421
    [No Abstract]   [Full Text] [Related]  

  • 13. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
    Karst KR
    Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 16. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Industry reneges on postmarketing trial commitments.
    Bouchie A
    Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
    [No Abstract]   [Full Text] [Related]  

  • 19. Avoiding the regulatory capture of the Food and Drug Administration.
    Egilman DS; Presler AH; Valentin CS
    Arch Intern Med; 2007 Apr; 167(7):732-3. PubMed ID: 17420438
    [No Abstract]   [Full Text] [Related]  

  • 20. Today's FDA.
    Slater EE
    N Engl J Med; 2005 Jan; 352(3):293-7. PubMed ID: 15659733
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.